Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Arecor Therapeutics PLC ( (GB:AREC) ) is now available.
Arecor Therapeutics has released its Annual Report and Accounts for the year ended 31 December 2025 and circulated them to shareholders, alongside the formal notice of its upcoming Annual General Meeting on 28 May in London. The documents are available on the company’s website, and shareholders are encouraged to participate in the AGM via an online platform for viewing while submitting their votes in advance by proxy, reflecting continued efforts to maintain engagement and governance access without requiring physical attendance.
By facilitating remote access to the AGM while keeping formal voting via proxy, Arecor is balancing shareholder participation with regulatory rigor and logistical practicality. This approach supports transparency for investors as the company progresses its pipeline of cardiometabolic therapies and reinforces its corporate governance framework during a critical clinical development phase.
Spark’s Take on AREC Stock
According to Spark, TipRanks’ AI Analyst, AREC is a Neutral.
The score is held down primarily by weak financial performance (sharp 2025 revenue decline, continued operating losses, and ongoing cash burn) and bearish technical signals (below major moving averages with negative MACD). A low-debt balance sheet provides some stability, but valuation is not a clear positive due to negative earnings and no dividend support.
To see Spark’s full report on AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a Cambridge, UK-based clinical-stage biotechnology company focused on developing advanced therapeutics to reduce treatment burden and improve outcomes for people with diabetes, obesity and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated, ultra-rapid-acting insulin being co-developed with Sequel Med Tech for use in automated insulin delivery systems, and the company is also advancing an oral peptide delivery platform targeting GLP-1 receptor agonists.
Average Trading Volume: 14,224
Technical Sentiment Signal: Sell
Current Market Cap: £24.92M
See more data about AREC stock on TipRanks’ Stock Analysis page.